André Vicente Esteves de Carvalho

André Vicente Esteves de Carvalho

Auto-generated profile, based on publicly available information

André Vicente Esteves de Carvalho

Hospital Moinhos de Vento, Porto Alegre, Brazil

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
MAMarcelo Arnone
Marcelo Arnone
MTMaria Denise Fonseca Takahashi
Maria Denise Fonseca Takahashi
ACAndré Vicente Esteves de Carvalho
André Vicente Esteves de Carvalho
WBWanderley Bernardo
Wanderley Bernardo
ABAline Lopes Bressan
Aline Lopes Bressan
TJTatiana Jerez Jaime
Tatiana Jerez Jaime
Psoriasis is a chronic inflammatory disease that affects 1.3% of the Brazilian population. The most common clinical manifestations are erythematous, scaling lesions that affect both genders and can occur on any anatomical site, preferentially involving the knees, elbows, scalp and genitals. Besides the impact on the quality of life, the systemic nature of the disease makes psoriasis an independent risk factor for cardiovascular disease, especially in young patients with severe disease. By an initiative of the Brazilian Society of Dermatology, dermatologists with renowned clinical experience in the management of psoriasis were invited to form a work group that, in a partnership with the Brazilian Medical Association, dedicated themselves to create the Plaque Psoriasis Diagnostic and Treatment Guidelines. The relevant issues for the diagnosis (evaluation of severity and comorbidities) and treatment of plaque psoriasis were defined. The issues generated a search strategy in the Medline-PubMed database up to July 2018. Subsequently, the answers to the questions of the recommendations were devised, and each reference selected presented the respective level of recommendation and strength of scientific evidence. The final recommendations for making up the final text were worded by the coordinators.

23 September 2021 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
RRRicardo Romiti
Ricardo Romiti
ACAndré Vicente E. de Carvalho
André Vicente E. de Carvalho
GDGleison V. Duarte
Gleison V. Duarte

12 November 2016 in Drugs in R&D
Verified
Journal Article
Open access
PDF file
ACAndré Vicente Esteves de Carvalho
André Vicente Esteves de Carvalho
RDRodrigo Pereira Duquia
Rodrigo Pereira Duquia
BHBernardo Lessa Horta
Bernardo Lessa Horta
RBRenan Rangel Bonamigo
Renan Rangel Bonamigo
Background Psoriasis is an immune-mediated inflammatory disease for which treatment has evolved over the past few years due to the introduction of immunobiologic and small molecule inhibitor medications. A better understanding of the comparative efficacies of drugs may help doctors to choose the most appropriate treatment for patients. Objective The aim of this study was to conduct a systematic review and meta-analysis to assess the efficacy of immunobiologic and small molecule inhibitor drugs for patients with moderate to severe psoriasis. Data Sources The EMBASE, PUBMED, LILACS, Web of Science and ClinicalTrials.org databases were searched for trials published to 21 July 2016. Study Selection Only randomized, double-blind, placebo-controlled clinical trials that evaluated the efficacy of immunobiologics or small molecule inhibitors for moderate to severe plaque-type psoriasis were selected by two independent authors. No restrictions were used. Data Extraction and Synthesis Two authors independently extracted the data and a random-effects model meta-analysis was performed. Main Outcomes and Measures The Psoriasis Area and Severity Index (PASI) 75 was considered the primary outcome, measured at the primary endpoint of each study. Results Thirty-eight studies were included in our analysis. The overall pooled effect favored biologics and small molecule inhibitors over placebo (risk difference [RD] 0.59, 95% confidence interval [CI] 0.58–0.60). Ixekizumab at a dose of 160 mg on week 0 and then every 2 weeks (RD 0.84, 95% CI 0.81–0.88), brodalumab 210 mg (RD 0.79, 95% CI 0.76–0.82), infliximab 5 mg/kg (RD 0.76, 95% CI 0.73–0.79), and secukinumab 300 mg (RD 0.76, 95% CI 0.71–0.81) showed a greater chance of response (PASI 75) when compared with placebo. Limitations The methodology of a traditional meta-analysis does not allow for drugs to be ranked. Included studies used short-term endpoints (10–16 weeks) to evaluate the primary outcome, therefore long-term efficacy could not be determined. Conclusions and Relevance The anti-IL-17 drugs brodalumab, ixekizumab and secukinumab showed an equal or greater chance of helping patients achieve a 75% improvement on PASI compared with other reviewed drugs.

10 March 2016 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
JWJ.J. Wu
J.J. Wu
CLC.W. Lynde
C.W. Lynde
CKC.E. Kleyn
C.E. Kleyn
LILars Iversen
Lars Iversen
JWJ.M van der Walt
J.M van der Walt
RBRobert Bissonnette
Robert Bissonnette

1 February 2012 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
RBRenan Rangel Bonamigo
Renan Rangel Bonamigo
ACAndré Vicente Esteves de Carvalho
André Vicente Esteves de Carvalho
VSVanessa Raquel Zaleski Sebastiani
Vanessa Raquel Zaleski Sebastiani
CSCristina Martino da Silva
Cristina Martino da Silva
APAngela Caroline de Zorzi Pinto
Angela Caroline de Zorzi Pinto
Skin cancer - melanoma and non melanoma - are common neoplasm with rising incidence over the last decades. It is an important public health problem. Its pathogenesis is not completely understood and the same happens with the genetic factors involved. The genes that encode the HLA are associated with some tumors and they may be responsible for one of the mechanisms that take part in the development of the before mentioned cancers. We have reviewed the literature on the subject of HLA antigens, melanoma and non melanoma skin cancer.

21 November 2012 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
ACAndré V. E. de Carvalho
André V. E. de Carvalho
RBRenan R. Bonamigo
Renan R. Bonamigo
CSCristina M. da Silva
Cristina M. da Silva
ÂPÂngela C. De Zorzi Pinto
Ângela C. De Zorzi Pinto